Goldman Sachs Initiates Coverage On Abbott Laboratories with Buy Rating, Announces Price Target of $121
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on Abbott Laboratories with a Buy rating and set a price target of $121.
May 30, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Abbott Laboratories with a Buy rating and set a price target of $121.
The initiation of coverage by a major financial institution like Goldman Sachs with a Buy rating and a specific price target is likely to positively influence investor sentiment and drive short-term price appreciation for Abbott Laboratories.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100